Identifying the Oxidative Stress-related Hub Genes in Dilated Cardiomyopathy by Bioinformatics Analysis.

INTRODUCTION Characterized as an idiopathic primary myocardial disorder, dilated cardiomyopathy (DCM) predominantly affects children and elderly adults. However, a lack of specific clinical symptoms and reliable biomarkers impedes timely diagnosis and rational clinical management of DCM.

Methods

Whole-genome expression profiles (GSE120895, GSE9800) were retrieved from the Gene Expression Omnibus database via the GEOquery R package. A series of bioinformatic methods were employed, including DEG, GSVA, WGCNA, GO/KEGG enrichment, PPI, and immune infiltration analysis. Key biomarkers were validated by qRT-PCR in a Doxorubicin (DOX)-induced DCM model.

Results

In total, 629 differentially expressed genes (DEGs) were screened out between DCM and control groups. Combined analysis of DEGs and WGCNA outputs identified 13 hub genes overlapping with oxidative stress-associated gene modules. Receiver Operating Characteristic (ROC) curve analyses confirmed that these hub genes exhibit favorable diagnostic efficiency for DCM. Functional enrichment results showed that these genes are mainly enriched in transmembrane transport and nucleotide metabolism pathways. Immune infiltration analysis indicated significantly elevated infiltration levels of five immune cell subsets in DCM myocardial tissues. In vivo experiments verified the significant upregulation of five core hub genes in DOX-induced DCM mice. By screening hub genes with diagnostic potency based on public transcriptome datasets and validating their expression alterations in a DOX-induced DCM animal model, this study provides partial experimental evidence to support the above bioinformatic outcomes.

Discussion

Through integrative analysis of multiple datasets and molecular biology validation, this study provides robust evidence supporting the involvement of these hub genes in DCM pathogenesis. Although validation was limited to a single murine model, the findings lay the groundwork for future mechanistic studies and clinical exploration of these candidate genes.

Conclusion

Hub genes including MVP, WISP1, FCN1, AMPD3, RARRES1, FTL, and KRT14 possess promising auxiliary diagnostic potential, which provides novel clues for subsequent clinical evaluation research on DCM.